Sam Brusco, Associate Editor05.19.23
Stereotaxis and Abbott have begun a collaboration to integrate Abbott’s EnSite XP EP system with Stereotaxis’ robotic magnetic navigation systems.
The combination merges detailed, real-time diagnostic information with the precision and stability of robotics during therapy delivery. The two companies have successfully finished integrating their technologies and performed testing, showing joint compatibility.
The integrated technologies were cleared in the EU with further regulatory clearances anticipated in the coming months.
"The combination of these two technologies is a seminal event for the community of physicians who have pioneered and championed robotics in electrophysiology,” Dr. J. Peter Weiss, electrophysiologist and clinical professor of medicine at Banner University of Arizona Medical Center, told the press. “Joint use of EnSite X with Robotic Magnetic Navigation is beneficial for the broad spectrum of cardiac ablation procedures and is most impactful in treating complex and challenging cardiac arrhythmias.”
Abbott's EnSite X System received FDA clearance in 2021. Robotic magnetic navigation introduces the benefits of robotic precision, stability, and safety to cardiac ablation procedures using advanced computer-controlled magnetic fields for direct control of a catheter tip.
“Stereotaxis is delighted to collaborate with Abbott and to be able to share this significant milestone for the electrophysiology field,” said David Fischel, chairman and CEO of Stereotaxis. “This collaboration further reinforces our commitment to meaningful innovations that advance the frontiers of medical progress. It provides additional choice for the community of robotic users and ensures patients, physicians and providers can benefit from the combination of the finest diagnostic and therapeutic technologies.”
The combination merges detailed, real-time diagnostic information with the precision and stability of robotics during therapy delivery. The two companies have successfully finished integrating their technologies and performed testing, showing joint compatibility.
The integrated technologies were cleared in the EU with further regulatory clearances anticipated in the coming months.
"The combination of these two technologies is a seminal event for the community of physicians who have pioneered and championed robotics in electrophysiology,” Dr. J. Peter Weiss, electrophysiologist and clinical professor of medicine at Banner University of Arizona Medical Center, told the press. “Joint use of EnSite X with Robotic Magnetic Navigation is beneficial for the broad spectrum of cardiac ablation procedures and is most impactful in treating complex and challenging cardiac arrhythmias.”
Abbott's EnSite X System received FDA clearance in 2021. Robotic magnetic navigation introduces the benefits of robotic precision, stability, and safety to cardiac ablation procedures using advanced computer-controlled magnetic fields for direct control of a catheter tip.
“Stereotaxis is delighted to collaborate with Abbott and to be able to share this significant milestone for the electrophysiology field,” said David Fischel, chairman and CEO of Stereotaxis. “This collaboration further reinforces our commitment to meaningful innovations that advance the frontiers of medical progress. It provides additional choice for the community of robotic users and ensures patients, physicians and providers can benefit from the combination of the finest diagnostic and therapeutic technologies.”